We constructed a subcutaneous mouse HCC model (Hepa1-6), a melanoma mouse model (B16F10), and a colon cancer mouse model (MC38) in Rig-I+/+ and Rig-I−/− C57BL/6J mice to further explore whether Rig-I knockout could improve the antitumor immunity of CD8+ T cells in vivo. Here, RIGI is linked to melanoma.